Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07465653) titled 'A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction' on March 6.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Novartis Pharmaceuticals
Condition:
Heart Failure With Reduced Ejection Fraction
Intervention:
Drug: HJB647 low dose
Drug: HJB647 high dose
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: March 19, 2026
Target Sample Size: 12
To know more, visit https://clinicaltrial...